Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.68 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042862 | 0.96 | MAPK14 (0.81) | ESR1ESR2MAPK14PTGS2KDM4E | |
| SCHEMBL22649305 | 0.89 | ESR1 (0.92) | ESR1ESR2MAPK14PTGS2EGFR | |
| SCHEMBL13461181 | 0.89 | ESR1 (0.92) | ESR1ESR2MAPK14PTGS2EGFR | |
| SCHEMBL29799621 | 0.89 | ESR1 (1.00) | ESR1ESR2MAPK14PTGS2EGFR | |
| SCHEMBL3864662 | 0.89 | ESR1 (1.00) | ESR1ESR2MAPK14PTGS2EGFR | |
| SCHEMBL17883133 | 0.88 | MAPK14 (0.70) | ESR1ESR2MAPK14PTGS2MAPK13 | |
| SCHEMBL6646016 | 0.87 | MAPK14 (1.00) | ESR1ESR2MAPK14PTGS2MAPK13 | |
| SCHEMBL6646025 | 0.87 | MAPK14 (1.00) | ESR1ESR2MAPK14PTGS2MAPK13 | |
| Carbazole SCHEMBL28000316 | 0.85 | ESR1 (0.92) | ESR1ESR2MAPK14PTGS2EGFR | |
| SCHEMBL7040942 | 0.84 | PTGS2 (0.72) | ESR1ESR2MAPK14PTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| EP-1817283-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | Lautens, Mark (CA) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006047888-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039625-A1 | Screening Methods | CBR3, ZKSCAN2, CRBN | ESR1 3078/4885ESR2 3149/4885MAPK14 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.